Huaku Development Co., Ltd. (TPE:2548)

CTI BioPharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,629	3,755	1,514	1,699	2,393	511.33
Short-Term Investments	-	2,000	-	-	-	-
Trading Asset Securities	11.69	13.39	32.27	143.17	168.37	122.47
Cash & Short-Term Investments	3,641	5,768	1,546	1,842	2,561	633.8
Cash Growth	91.09%	273.15%	-16.10%	-28.07%	304.13%	-52.18%
Accounts Receivable	364.95	220.45	175.69	144.18	197.54	252.54
Other Receivables	140.23	12.57	11	12.04	26.88	67
Receivables	505.18	233.01	186.69	156.22	224.42	319.54
Inventory	46,892	43,989	36,500	34,176	34,543	28,958
Prepaid Expenses	202.17	204.35	109.1	92.27	28.35	109.68
Other Current Assets	3,299	3,673	2,301	1,847	1,515	2,020
Total Current Assets	54,539	53,868	40,643	38,114	38,872	32,041
Property, Plant & Equipment	373.04	321.42	228.67	226.17	219.74	207.86
Long-Term Investments	68.52	68.47	66.03	44.61	41.06	41.06
Long-Term Accounts Receivable	-	1,898	2,151	2,493	2,850	3,276
Long-Term Deferred Tax Assets	21.72	24.45	24.23	24.26	27	27.81
Other Long-Term Assets	2,086	322.14	479.15	657.32	619.59	603.93
Total Assets	57,088	56,503	43,592	41,559	42,629	36,198
Accounts Payable	1,590	1,869	1,699	1,314	1,335	1,260
Short-Term Debt	18,383	17,128	12,112	9,052	11,083	5,899
Current Portion of Long-Term Debt	-	1,318	1,293	2,564	2,512	2,127
Current Portion of Leases	11.89	19.53	12.4	11.49	6.81	9.95
Current Income Taxes Payable	83.26	364.13	327.05	444.35	516.94	190.22
Current Unearned Revenue	6,567	6,012	3,725	4,647	3,726	3,468
Other Current Liabilities	3,242	498.03	702.5	782.31	752.73	688.67
Total Current Liabilities	29,877	27,208	19,871	18,814	19,932	13,643
Long-Term Debt	7,672	8,285	2,839	3,289	4,072	4,897
Long-Term Leases	9.92	24.05	16.59	7.8	11.63	3.02
Long-Term Unearned Revenue	-	-	-	4.6	26.39	58.95
Long-Term Deferred Tax Liabilities	8.74	9.42	3.51	3.56	2.28	3.18
Other Long-Term Liabilities	113.83	123.9	66.34	69.06	71.58	64.12
Total Liabilities	37,682	35,650	22,797	22,188	24,116	18,670
Common Stock	3,045	3,045	2,768	2,768	2,768	2,768
Additional Paid-In Capital	820.04	818.99	80.73	78.99	77.68	75.88
Retained Earnings	15,349	16,945	17,917	16,412	15,527	14,541
Treasury Stock	-0.85	-0.85	-0.85	-0.85	-0.85	-0.85
Comprehensive Income & Other	185.93	35.98	11.94	11.67	6.09	9.32
Total Common Equity	19,399	20,844	20,777	19,270	18,378	17,393
Minority Interest	6.51	8.71	18.49	101.86	134.83	134.21
Shareholders' Equity	19,406	20,852	20,795	19,372	18,513	17,528
Total Liabilities & Equity	57,088	56,503	43,592	41,559	42,629	36,198
Total Debt	26,077	26,774	16,273	14,923	17,686	12,936
Net Cash (Debt)	-22,437	-21,006	-14,727	-13,081	-15,124	-12,303
Net Cash Per Share	-65.92	-65.60	-45.85	-40.71	-47.09	-38.31
Filing Date Shares Outstanding	320.67	319.52	319.52	319.52	319.52	319.52
Total Common Shares Outstanding	320.67	319.52	319.52	319.52	319.52	319.52
Working Capital	24,662	26,660	20,771	19,300	18,940	18,398
Book Value Per Share	60.50	65.23	65.03	60.31	57.52	54.44
Tangible Book Value	19,399	20,844	20,777	19,270	18,378	17,393
Tangible Book Value Per Share	60.50	65.23	65.03	60.31	57.52	54.44

Source: S&P Global Market Intelligence. Standard template. Financial Sources.